MGTXMeiraGTx Holdings plc

1. Sep 23, 2026On September 22, 2026, the Board of Directors (the “Board”) of MeiraGTx Holdings plc (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026, with a term that expires at the Company’s 2028 …Director or officer change · Form 8-K
2. Aug 13, 2026MeiraGTx Reports Second Quarter 2026 Financial and Operational Results.Earnings release · press release
3. Jul 7, 2026Royalty Note Purchase Agreement On June 30, 2026, MeiraGTx Holdings plc (the “Company”) and certain of its subsidiaries entered into a Royalty Note Purchase Agreement (the “Royalty Note Purchase Agreement”), by and among MeiraGTx, LLC, as issuer, the Company and certain of its subsidiaries, as obligors (collectively …Material agreement entered · Form 8-K
4. May 14, 2026MeiraGTx Reports First Quarter 2026 Financial and Operational Results.Earnings release · press release
5. Apr 24, 2026Hologen Transactions On April 20, 2026 (the “Initial Closing Date”), MeiraGTx Holdings plc (the “Company”) and certain of its affiliates completed the initial closing of the strategic collaboration with Hologen Limited, a non-cellular company limited by shares incorporated in Guernsey (“Hologen”), and certain of its …Material agreement entered · Form 8-K
6. Apr 16, 2026On April 16, 2026, MeiraGTx Holdings plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Underwriters”), in connection with the issuance and sale by the Company in an offering of 11,111,111 ordinary shares of the Company …Material agreement entered · Form 8-K
7. Apr 16, 2026Janssen Asset Purchase Agreement On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a company incorporated in England and Wales (“MeiraGTx Ocular” and together with the Company, collectively the “Buyer”), entered into and …Material agreement entered · Form 8-K
8. Apr 16, 2026Recent Developments On April 16, 2026, the Company announced positive 3-year data from the Company’s Phase 1 AQUAx clinical study of AAV-hAQP1 for the treatment of grade 2/3 radiation induced xerostomia.Regulation FD disclosure · Form 8-K
9. Mar 26, 2026On March 25, 2026, MeiraGTx Holdings plc (the “Company”), as issuer, and its wholly-owned subsidiaries MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), and MeiraGTx Ireland DAC, a designated activity company limited by shares incorporated in Ireland (“MeiraGTx Ireland,” and …Material agreement entered · Form 8-K
10. Jan 2, 2026On December 31, 2025, MeiraGTx Holdings plc (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd. (“Perceptive Master Fund”), an affiliate of Perceptive Advisors LLC (“Perceptive Advisors”), pursuant to which the Company agreed to …Material agreement entered · Form 8-K
11. Nov 13, 2025MeiraGTx Reports Third Quarter 2025 Financial and Operational Results.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.